Kyntra Bio Inc Com (New) (KYNB:NASDAQ) closed at $3.44 on November 13, 2026, down 6.01% on the day. The stock trades 67.1% below its 52-week high of $10.47 and 3.0% above its 52-week low of $3.34. Over the past year, it lost 60.5%. Kyntra Bio Inc Com (New) is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, KYNB closed higher on 104 days (41%). Its best day was December 15, 2025 (+19.81%) and its worst was October 23, 2026 (-12.26%). The stock moved 10% or more in a single session 2 times.
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (¿¿¿®, EVRENZO¿) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker.
Find more stocks like KYNB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.